RE:RE:Potential Pool of New Investors?Yeah Guys, congrats! I think once data begins to come out on US patients, we're off to the moon. I agree with ya Doc, weather FT or BTD we'll get that comercialization go ahead from the FDA in a bit more than a year. Good times ahead. And what an unforseen blessing our trial doesn't include chemo or anything that would impact the immune system during this pandemic. That alone should get people interested.
Hempdoc wrote:
Hankerchief wrote: Perhaps as the sites in the USA start getting some attention there may be some new investors taking interest....eg those directly and even indirectly involved with treating the study patients and word of mouth. Seems like any new money brought in at these price levels would be considered very lucky to have this opportunity. I wish I would have heard about Theralase a week ago instead of a few years back when I paid double the price it is now. Oh well. Fill that gap fast and run !
Late to the party...Congrats everyone : )
I am EXTREMELY HAPPY...This IND approval arriving "on time" (especially in the midst of a Pandemic) is a really BIG win imo. Covid-19 threw a big wrench into the progress of not only our trial, but also our IND...& I'm certain that IND approval required all sorts of "new" contingency measures/protocol adaptations...so very happy & don't care too much about a few penny difference in sp...will be loading up tomorrow!
Expect to see USA sites up & running soon (particularly the TMO sites), considering they don't have a provincial government breathing down their backs ; ). In terms of a restart date, we should be given some priority simply based on the fact our ACT does not suppress the immune system (like trials using chemo or immunotherapy). There is also no universal guideline for restarting, but I imagine USA trial decisions will primarily be driven by each corresponding review board/ethics committee & clinical investigator. I also anticipate fast track status is just around the corner, which will provide added support during this crisis in addition to DMC correspondence. The silver lining of this pandemic will likely include a longer leash (in terms of unexpected modifications to protocols/operations, etc. while under the influences of a pandemic), less of "the usual" trial bureaucracy, & hopefully a faster path to approval (especially considering the dismal results obtained thus far by our immunotherapy competitors) JMO. Good luck...